vs
BigBear.ai Holdings, Inc.（BBAI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是BigBear.ai Holdings, Inc.的1.1倍（$30.3M vs $27.3M），REGENXBIO Inc.同比增速更快（43.0% vs -37.7%），BigBear.ai Holdings, Inc.自由现金流更多（$-22.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -9.2%）
BigBear.ai Holdings, Inc.是一家专注于人工智能决策支持与分析解决方案的服务商，核心产品包括预测分析、供应链优化、运营智能平台，服务国防、情报机构及商业企业客户，主要市场覆盖北美，助力客户提升运营效率、降低运营风险。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BBAI vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.1倍
$27.3M
营收增速更快
RGNX
高出80.7%
-37.7%
自由现金流更多
BBAI
多$30.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-9.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $27.3M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | 20.3% | — |
| 营业利润率 | -295.0% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | -37.7% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.17 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBAIRGNX
| Q4 25 | $27.3M | $30.3M | ||
| Q3 25 | $33.1M | $29.7M | ||
| Q2 25 | $32.5M | $21.4M | ||
| Q1 25 | $34.8M | $89.0M | ||
| Q4 24 | $43.8M | $21.2M | ||
| Q3 24 | $41.5M | $24.2M | ||
| Q2 24 | $39.8M | $22.3M | ||
| Q1 24 | $33.1M | $15.6M |
净利润BBAIRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $2.5M | $-61.9M | ||
| Q2 25 | $-228.6M | $-70.9M | ||
| Q1 25 | $-62.0M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-15.1M | $-59.6M | ||
| Q2 24 | $-14.4M | $-53.0M | ||
| Q1 24 | $-127.8M | $-63.3M |
毛利率BBAIRGNX
| Q4 25 | 20.3% | — | ||
| Q3 25 | 22.4% | — | ||
| Q2 25 | 25.0% | — | ||
| Q1 25 | 21.3% | — | ||
| Q4 24 | 37.4% | 70.2% | ||
| Q3 24 | 25.9% | 48.8% | ||
| Q2 24 | 27.8% | 52.5% | ||
| Q1 24 | 21.1% | 72.6% |
营业利润率BBAIRGNX
| Q4 25 | -295.0% | -190.0% | ||
| Q3 25 | -66.0% | -176.3% | ||
| Q2 25 | -278.1% | -296.3% | ||
| Q1 25 | -61.0% | 13.6% | ||
| Q4 24 | -18.6% | -242.1% | ||
| Q3 24 | -25.4% | -256.6% | ||
| Q2 24 | -41.9% | -251.3% | ||
| Q1 24 | -296.1% | -408.8% |
净利率BBAIRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 7.6% | -208.3% | ||
| Q2 25 | -704.0% | -331.8% | ||
| Q1 25 | -178.3% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -36.5% | -246.3% | ||
| Q2 24 | -36.3% | -237.7% | ||
| Q1 24 | -385.8% | -405.4% |
每股收益（稀释后）BBAIRGNX
| Q4 25 | $0.17 | $-1.30 | ||
| Q3 25 | $-0.03 | $-1.20 | ||
| Q2 25 | $-0.71 | $-1.38 | ||
| Q1 25 | $-0.25 | $0.12 | ||
| Q4 24 | $-0.47 | $-0.99 | ||
| Q3 24 | $-0.06 | $-1.17 | ||
| Q2 24 | $-0.06 | $-1.05 | ||
| Q1 24 | $-0.68 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.1M | $230.1M |
| 总债务越低越好 | $107.0M | — |
| 股东权益账面价值 | $611.9M | $102.7M |
| 总资产 | $894.5M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资BBAIRGNX
| Q4 25 | $87.1M | $230.1M | ||
| Q3 25 | $456.6M | $274.2M | ||
| Q2 25 | $390.8M | $323.3M | ||
| Q1 25 | $107.6M | $267.9M | ||
| Q4 24 | $50.1M | $234.7M | ||
| Q3 24 | $65.6M | $255.5M | ||
| Q2 24 | $72.3M | $290.4M | ||
| Q1 24 | $81.4M | $338.7M |
总债务BBAIRGNX
| Q4 25 | $107.0M | — | ||
| Q3 25 | $104.9M | — | ||
| Q2 25 | $103.0M | — | ||
| Q1 25 | $101.4M | — | ||
| Q4 24 | $136.2M | — | ||
| Q3 24 | $195.7M | — | ||
| Q2 24 | $195.7M | — | ||
| Q1 24 | $195.6M | — |
股东权益BBAIRGNX
| Q4 25 | $611.9M | $102.7M | ||
| Q3 25 | $610.0M | $161.5M | ||
| Q2 25 | $266.6M | $213.7M | ||
| Q1 25 | $197.8M | $274.2M | ||
| Q4 24 | $-3.7M | $259.7M | ||
| Q3 24 | $127.5M | $301.4M | ||
| Q2 24 | $134.7M | $348.3M | ||
| Q1 24 | $143.2M | $390.7M |
总资产BBAIRGNX
| Q4 25 | $894.5M | $453.0M | ||
| Q3 25 | $919.8M | $525.2M | ||
| Q2 25 | $599.4M | $581.0M | ||
| Q1 25 | $396.3M | $490.9M | ||
| Q4 24 | $343.8M | $466.0M | ||
| Q3 24 | $354.1M | $519.1M | ||
| Q2 24 | $360.9M | $569.4M | ||
| Q1 24 | $377.6M | $629.2M |
负债/权益比BBAIRGNX
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.39× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.45× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-21.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-22.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -80.9% | -174.0% |
| 资本支出强度资本支出/营收 | 0.9% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-42.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BBAIRGNX
| Q4 25 | $-21.8M | $-52.3M | ||
| Q3 25 | $-9.6M | $-56.0M | ||
| Q2 25 | $-3.9M | $-49.3M | ||
| Q1 25 | $-6.7M | $33.6M | ||
| Q4 24 | $-14.8M | $-31.6M | ||
| Q3 24 | $-1.9M | $-40.5M | ||
| Q2 24 | $-7.1M | $-45.5M | ||
| Q1 24 | $-14.4M | $-55.5M |
自由现金流BBAIRGNX
| Q4 25 | $-22.1M | $-52.8M | ||
| Q3 25 | $-9.8M | $-56.5M | ||
| Q2 25 | $-3.9M | $-49.7M | ||
| Q1 25 | $-6.7M | $32.6M | ||
| Q4 24 | $-15.0M | $-32.7M | ||
| Q3 24 | $-2.0M | $-40.9M | ||
| Q2 24 | $-7.2M | $-46.0M | ||
| Q1 24 | $-14.4M | $-56.0M |
自由现金流率BBAIRGNX
| Q4 25 | -80.9% | -174.0% | ||
| Q3 25 | -29.5% | -189.9% | ||
| Q2 25 | -11.9% | -232.8% | ||
| Q1 25 | -19.4% | 36.6% | ||
| Q4 24 | -34.2% | -154.2% | ||
| Q3 24 | -4.9% | -168.9% | ||
| Q2 24 | -18.1% | -206.2% | ||
| Q1 24 | -43.5% | -358.5% |
资本支出强度BBAIRGNX
| Q4 25 | 0.9% | 1.7% | ||
| Q3 25 | 0.6% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.4% | 5.1% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 0.1% | 3.6% |
现金转化率BBAIRGNX
| Q4 25 | — | — | ||
| Q3 25 | -3.80× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BBAI
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
